ZUMA-1 研究中高龄患者的结局，该研究为 axicabtagene ciloleucel 治疗难治性大 B 细胞淋巴瘤的关键研究。
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
机构信息
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Boston, MA.
出版信息
Blood. 2020 Jun 4;135(23):2106-2109. doi: 10.1182/blood.2019004162.
Abstract
There is a Commentary on this article in this issue.
摘要
本期对这篇文章有评论。
相似文献
1
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 研究中高龄患者的结局，该研究为 axicabtagene ciloleucel 治疗难治性大 B 细胞淋巴瘤的关键研究。
Blood. 2020 Jun 4;135(23):2106-2109. doi: 10.1182/blood.2019004162.
2
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
3
Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.阿基仑赛注射液，一种针对复发或难治性大 B 细胞淋巴瘤的抗 CD19 嵌合抗原受体 T 细胞疗法：对社区肿瘤医生的实际影响。
Oncologist. 2020 Jan;25(1):e138-e146. doi: 10.1634/theoncologist.2019-0395. Epub 2019 Oct 4.
4
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.CD19 靶向 CAR-T 细胞疗法治疗复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和安全性：来自 JULIET、ZUMA-1 和 TRANSCEND 试验的观察结果。
Am J Hematol. 2021 Oct 1;96(10):1295-1312. doi: 10.1002/ajh.26301. Epub 2021 Aug 13.
5
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.接受axi-cabtagene ciloleucel治疗后病情进展的大B细胞淋巴瘤患者的预后
Blood. 2021 Apr 1;137(13):1832-1835. doi: 10.1182/blood.2020006245.
6
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.阿基卡宾赛妥昔单抗在非临床试验环境下的疗效、耐药性和毒性的结果和相关性。
J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15.
7
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.ZUMA-5（阿基仑赛）与 SCHOLAR-5 治疗复发性/难治性滤泡性淋巴瘤的 3 年随访结果比较。
Clin Lymphoma Myeloma Leuk. 2024 May;24(5):e191-e195.e6. doi: 10.1016/j.clml.2024.01.011. Epub 2024 Jan 24.
8
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).ZUMA-5 研究：复发/难治性惰性非霍奇金淋巴瘤中 axicabtagene ciloleucel 的 3 年随访分析。
Blood. 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243.
9
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.嵌合抗原受体 T 细胞疗法 Axicabtagene Ciloleucel 治疗大 B 细胞淋巴瘤的研发与应用：综述。
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
10
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 的 5 年随访结果支持 axi-cel 在难治性大 B 细胞淋巴瘤中的治疗潜力。
Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893.
引用本文的文献
1
Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis.弥漫性大B细胞淋巴瘤患者的生存结局及影响生存的因素：一项基于人群的分析。
Blood Neoplasia. 2025 May 19;2(3):100117. doi: 10.1016/j.bneo.2025.100117. eCollection 2025 Aug.
2
Prophylactic Tocilizumab prior to infusion of CD19 CAR T-cells reduces therapy-related complications in older lymphoma patients.在输注CD19嵌合抗原受体T细胞之前使用托珠单抗进行预防，可降低老年淋巴瘤患者的治疗相关并发症。
Ann Hematol. 2025 Jul 25. doi: 10.1007/s00277-025-06511-x.
3
Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma.系统文献综述以确定嵌合抗原受体T细胞疗法治疗弥漫性大B细胞淋巴瘤疗效和安全性结果的预后因素。
J Cancer Res Clin Oncol. 2025 Jul 7;151(7):203. doi: 10.1007/s00432-025-06249-z.
4
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.老年复发/难治性大B细胞淋巴瘤患者的CAR-T细胞疗法：益处与挑战
J Immunother Cancer. 2025 Jun 5;13(6):e009793. doi: 10.1136/jitc-2024-009793.
5
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).《日本血液学会2023年血液系统恶性肿瘤实用指南：II. 淋巴瘤5. 未另行指定的弥漫性大B细胞淋巴瘤（DLBCL，NOS）》
Int J Hematol. 2025 May 28. doi: 10.1007/s12185-025-03997-z.
6
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.对嵌合抗原受体T细胞（CAR T）的持久反应与细胞毒性天然T细胞库的激活增强和克隆型扩增有关。
Nat Commun. 2025 May 23;16(1):4819. doi: 10.1038/s41467-025-59904-x.
7
Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies.老年评估在造血干细胞移植和细胞治疗中的作用。
Curr Treat Options Oncol. 2025 May;26(5):348-359. doi: 10.1007/s11864-025-01316-6. Epub 2025 Apr 10.
8
Challenges in Multiple Myeloma Therapy in Older and Frail Patients.老年和体弱患者多发性骨髓瘤治疗中的挑战
Cancers (Basel). 2025 Mar 11;17(6):944. doi: 10.3390/cancers17060944.
9
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.3期POLARIX研究中年龄≥60岁的弥漫性大B细胞淋巴瘤老年患者的亚组分析。
Blood Adv. 2025 May 27;9(10):2489-2499. doi: 10.1182/bloodadvances.2024014707.
10
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.获批的针对大B细胞淋巴瘤的CD19靶向嵌合抗原受体T细胞的疗效相关因素。
Nat Rev Clin Oncol. 2025 Apr;22(4):241-261. doi: 10.1038/s41571-025-00992-5. Epub 2025 Feb 18.
本文引用的文献
1
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
2
Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.自体干细胞移植在 70 多岁老年淋巴瘤患者中的应用：结果与分析。
Oncologist. 2018 May;23(5):624-630. doi: 10.1634/theoncologist.2017-0499. Epub 2017 Dec 28.
3
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
4
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.难治性弥漫性大B细胞淋巴瘤的预后：国际SCHOLAR-1研究结果
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
5
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.ZUMA-1的1期研究结果：一项关于KTE-C19抗CD19嵌合抗原受体T细胞疗法治疗难治性侵袭性淋巴瘤的多中心研究
Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020.
6
Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians.老年癌症患者化疗决策困难：癌症医师普查。
Crit Rev Oncol Hematol. 2011 Apr;78(1):45-58. doi: 10.1016/j.critrevonc.2010.02.010. Epub 2010 Mar 23.
7
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.1992 - 2001年美国按世界卫生组织亚型划分的淋巴瘤发病模式。
Blood. 2006 Jan 1;107(1):265-76. doi: 10.1182/blood-2005-06-2508. Epub 2005 Sep 8.
8
A predictive model for aggressive non-Hodgkin's lymphoma.侵袭性非霍奇金淋巴瘤的预测模型。
N Engl J Med. 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402.
Zotero 插件